Drugmaker Pfizer hikes 2024 forecast again after initially underwhelming Wall Street

Pfizer now expects 2024 earnings to wind up well above analyst expectations after starting the year with a forecast that disappointed Wall Street.

The drugmaker also said Tuesday that sales growth for non-COVID related drugs like the blood thinner Eliquis helped it deliver a better-than-expected performance in the recently concluded second quarter.

Company shares climbed in early morning trading.

Overall, the drugmaker’s net income tumbled 98% to $41 million in the quarter...